An interventional study of Placebo and HydroCurc® in Iron Supplementation and Gastrointestinal Health and Iron Deficiency, sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-21.
Sponsored by University of Westminster · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Iron Deficiencies with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Iron Deficiencies · United Kingdom.
Among the 22 studies in Iron Deficiencies with a site in United Kingdom, this one is the 18th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 11 with no phase, and was the 22nd registered.
386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.
Browse Iron Deficiencies studies →2 of the 22 studies in Iron Deficiencies with a site in United Kingdom are open now. Recruiting first, the newest first:
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Quadram Institute Bioscience · Sites in United Kingdom
Ages 18–60 · Women only · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 50 across the 19 interventional studies, 379 across the 3 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
University of Westminster is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
University of Westminster has 2 studies filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Iron Deficiencies with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Iron deficiency and iron deficiency anaemia are common among endurance athletes partly due to a repeated post-exercise elevation of hepcidin, a hormone limiting iron entry through the intestine. Oral iron supplementation also causes stimulation of hepcidin that adds on to the exercise-intrinsic stimulation of this hormone further reducing iron absorption. Both oral ferrous iron therapy and performance running are known to cause undesired gastrointestinal symptoms. Curcumin, a polyphenol from turmeric, has been previously shown to reduce hepcidin levels in resting individuals and to protect the gastrointestinal (GI) function but its effect on active individuals supplementing with iron remains unclarified.
The objective of this research study is to learn about the effects of a formulated curcumin (HydroCurc®) on intestinal health and regulation mechanisms of body iron levels in recreationally active athletes supplementing with iron.
The main questions to answer are:
Does HydroCurc® influence iron regulatory mechanisms in resting conditions? Does HydroCurc® influence iron regulatory mechanisms in post-exercise conditions? Does HydroCurc® alleviate iron supplementation- and exercise-related gastrointestinal adverse events
Researchers will compare HydroCurc® to a placebo (a look-alike substance that contains no drug) to see if there are any significant changes.
Participants will:
Intervention study with two treatment groups in a randomised, double-blinded, placebo-controlled, crossover design.
Healthy recreationally active athletes will perform a VO2 max test to determine their aerobic capacity. A blood sample will be taken prior to the test as baseline measurement. Following treatment with iron plus either HydroCurc or a matched placebo for a week, participants will run on a treadmill for one hour at 70% of their maximal capacity. Blood samples will be collected before, immediately after, one hour post- and three hours post-exercise. Gastrointestinal symptoms will be assessed via validated questionnaires during the supplementation period and the experimental visits. All participants will observe a minimum of a two-week washout period. All participants will attend visits fasting for a minimum of four hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
These criteria will be self-reported.
* Dried ferrous sulphate tablet, 200mg providing 65 mg of elemental iron (Remedy Healthcare, UK). * Placebo capsule containing maltodextrin and a food grade dye (yellow 5 or E102) (Fast Colours LLP, Huddersfield, UK)
Dietary Supplement: Placebo · Dietary Supplement: Ferrous sulphate 200mg oral tablet providing 65 mg of elemental iron
* Dried ferrous sulphate, 200mg tablet providing 65 mg of elemental iron (Remedy Healthcare, UK). * HydroCurc (Gencor Pacific Limited, Lantau Island, Hong Kong), 500 mg capsule containing not less than 90% 115 curcuminoids (85% curcumin), formulated in 10% LipiSperse® (Pharmako Biotechnologies Pty Ltd, 116 Sydney, Australia), a delivery system comprising a proprietary mixture of surfactants, polar lipids 117 and solvents.
Dietary Supplement: HydroCurc® · Dietary Supplement: Ferrous sulphate 200mg oral tablet providing 65 mg of elemental iron
Participants instructed to intake the placebo capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
Participants instructed to intake the HydroCurc® capsule along with the ferrous sulphate tablet, separated from food, tea or coffee, at the same time of the day.
Participants instructed to intake the ferrous sulphate tablet along with the HydroCurc® or the placebo together, preferably and separated from food, tea or coffee, at the same time of the day.
Concentration of iron absorption regulatory hormone in athletes supplementing with ferrous iron in resting conditions
Hepcidin, ng/mL
Time frame: Hepcidin measured 1 day post supplementation
Exercise-associated hepcidin concentration in athletes supplementing with ferrous iron
Hepcidin, ng/mL
Time frame: Hepcidin measured 180 minutes post-exercise
Ferrous iron-associated iron status in athletes
Ferritin, ng/mL
Time frame: Ferritin measured 1 day post supplementation
Change of exercise-associated inflammation in ferrous iron supplemented athletes
Interleukin-6, pg/mL
Time frame: Interleukin-6 measured 0- and 60-minutes post-exercise
Exercise-associated intestinal damage in ferrous iron supplemented athletes
Intestinal Fatty Acid Binding Protein (IFABP), pg/mL
Time frame: IFABP measured 0- and 60-minutes post-exercise
Incidence and frequency of ferrous iron associated-gastrointestinal symptoms
Subjective analysis via Oral Iron Supplement Questionnaire
Time frame: Gastrointestinal symptoms analysed daily throughout the supplementation period (seven continuous days)
Number of participants supplementing with ferrous iron and reporting exercise-associated gastrointestinal symptoms
Subjective analysis via gastrointestinal symptom questionnaire
Time frame: Gastrointestinal symptoms measured 30 minutes after the commencement of the exercise, 0-, 60- and 180- minutes post-exercise.
Plan to share: No
Ran from Oct 2023 to primary completion in Jan 2024, 3 months.
Of 77 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 3 months is below that.
Counting every sponsor, half of 89 studies reached it within 10 months; a quarter within 5 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Westminster